Celldex Therapeutics, Inc. (NASDAQ: CLDX) is considered one of the best small-cap stocks with significant upside potential.
On October 13, Barclays initiated coverage of Celldex Therapeutics, assigning an Underweight rating to the stock. The firm set a price target of $25 per share.
This rating was part of Barclays’ broader launch of coverage on eight companies across sectors including rare diseases and inflammation.
https://www.insidermonkey.com/blog/barclays-initiates-coverage-of-celldex-therapeutics-cldx-with-an-underweight-rating-1630306/
